Please ensure Javascript is enabled for purposes of website accessibility

2 Pharma Stocks You Should Buy Now

By Prosper Junior Bakiny – Sep 21, 2019 at 2:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Both Vertex and Merck dominate their respective segments of the pharmaceutical market.

The pharmaceutical industry is important for one simple reason: we are all, at some point, in need of medical treatment, and the amount of money that is spent on drugs continues to increase. Until we stumble upon a way to eradicate illnesses altogether, that isn't going to change. Though we can't escape from this sad reality, we may profit from it by investing in pharmaceutical companies that develop state of the art prescription drugs. Obviously, there are dozens of pharma stocks to choose from, but two that I think present particularly strong prospects are Vertex Pharmaceuticals (VRTX 2.73%) and Merck (MRK 1.66%)

Vertex stock molecular compounds

Image source: Getty Images

Dominating the cystic fibrosis market

Vertex' annual revenues have increased by more than 400% since 2014. Over the same period, the firm turned a net loss of $739 million to a profit of over $2 billion, and its share price grew by about 130%.

This performance can be attributed to its monopoly on the market for drugs that treat cystic fibrosis (CF). The rare genetic condition affects upward of 75,000 people worldwide, according to some estimates.

All of Vertex' approved drugs -- Kalydeco, Orkambi, and Symdeko -- treat the underlying causes of CF. Unfortunately, all three drugs are limited in their scope to treat the rare lung disease. As we speak, only about 39,000 of those living with CF are eligible for one of Vertex' drugs, and the number of patients actually taking these medicines is likely a lot lower. There is some good news, though. Back in May, the pharma company announced positive results from a Phase 3 study for a trio of new drugs that could treat up to 90% of patients with CF. 

Vertex' application for these drugs -- VX-445, Tezacaftor, and Ivacaftor -- will likely receive approval from the FDA by early 2020. This new development could help the firm sustain strong top line growth as the market for its drugs expands substantially. Further, Vertex is looking for ways to diversify its product offerings. The company's pipeline includes various pain medications, and a treatment for alpha-1 antitrypsin deficiency, a condition that raises the risk for lung disease. Finally, Vertex recently acquired privately held biotech company Semma Therapeutics with the ambitious goal of finding a cure for type 1 diabetes. Of course, there is no guarantee that this partnership will produce anything fruitful, but if it does, Vertex would reap the benefits for many years to come. 

The soon-to-be world's best selling drug?

Over the past few years, Merck's key growth driver has been none other than Keytruda. The pharma company's top selling product is approved for a range of cancers, including gastric cancer, esophageal cancer, small cell lung cancer, non-small cell lung cancer, head and neck cancer, among others.

What's more, there are still dozens of clinical trials involving Keytruda, which means the cancer drug has a bright future ahead. Sales of Keytruda have increased by more than 5000% since 2014. After ranking third on the list of world's top selling drugs last year, Keytruda is projected to take the top spot by 2024 as the current top selling medicine -- AbbVie's (ABBV 3.06%) Humira -- faces stiff competition from biosimilars in Europe. 

Though Keytruda makes up the lion's share of Merck's revenues, the firm has other products to rely on. In particular, Merck's vaccines business is booming. The company's Gardasil and Gardasil 9 -- which prevent certain cancers and other diseases caused by HPV -- saw their combined second quarter sales soar by 46% year-over-year. Merck's package of several vaccines that help prevent diseases such as measles, mumps, rubella, chickenpox, and varicella also grew by 58% compared to the previous year.

Lastly, Merck has several ongoing partnerships with other pharma companies. Last year, the FDA approved Lynparza, a treatment for ovarian cancer and breast cancer Merck markets with AstraZeneca (AZN 1.29%). The potential clientele for this medicine is vast, and it could help Merck decrease its top line exposure to Keytruda. 

Are they buys?

Vertex' hold on the market for drugs that treat CF will likely continue pushing its earnings upward, especially considering the market for its medicines will become much larger. Meanwhile, Merck's Keytruda is on pace to become the world's best selling drug by 2024. While both companies could run into problems if their top selling products start encountering strong competition, the near to mid-term landscape looks relatively bright for these pharma stocks. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$87.55 (1.66%) $1.43
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$297.43 (2.73%) $7.89
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$55.55 (1.29%) $0.71
AbbVie Inc. Stock Quote
AbbVie Inc.
$138.32 (3.06%) $4.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.